JP2018513368A - 認知力低下のリスクを予測するための方法 - Google Patents

認知力低下のリスクを予測するための方法 Download PDF

Info

Publication number
JP2018513368A
JP2018513368A JP2017551127A JP2017551127A JP2018513368A JP 2018513368 A JP2018513368 A JP 2018513368A JP 2017551127 A JP2017551127 A JP 2017551127A JP 2017551127 A JP2017551127 A JP 2017551127A JP 2018513368 A JP2018513368 A JP 2018513368A
Authority
JP
Japan
Prior art keywords
iron
level
brain
patient
ferritin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017551127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513368A5 (enExample
Inventor
スコット・エイトン
ノエル・フォー
アシュリー・イアン・ブッシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crc For Mental Health Ltd
Original Assignee
Crc For Mental Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901210A external-priority patent/AU2015901210A0/en
Application filed by Crc For Mental Health Ltd filed Critical Crc For Mental Health Ltd
Publication of JP2018513368A publication Critical patent/JP2018513368A/ja
Publication of JP2018513368A5 publication Critical patent/JP2018513368A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0048—Detecting, measuring or recording by applying mechanical forces or stimuli
    • A61B5/0055—Detecting, measuring or recording by applying mechanical forces or stimuli by applying suction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
    • A61B5/4064—Evaluating the brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Developmental Disabilities (AREA)
JP2017551127A 2015-04-02 2016-04-01 認知力低下のリスクを予測するための方法 Pending JP2018513368A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2015901210 2015-04-02
AU2015901210A AU2015901210A0 (en) 2015-04-02 Method for predicting risk of cognitive deterioration
AU2016900347A AU2016900347A0 (en) 2016-02-03 Method for predicting risk of cognitive deterioration
AU2016900347 2016-02-03
PCT/AU2016/050248 WO2016154682A1 (en) 2015-04-02 2016-04-01 Method for predicting risk of cognitive deterioration

Publications (2)

Publication Number Publication Date
JP2018513368A true JP2018513368A (ja) 2018-05-24
JP2018513368A5 JP2018513368A5 (enExample) 2019-05-09

Family

ID=57003726

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017551127A Pending JP2018513368A (ja) 2015-04-02 2016-04-01 認知力低下のリスクを予測するための方法

Country Status (9)

Country Link
US (1) US20180284141A1 (enExample)
EP (1) EP3278113A4 (enExample)
JP (1) JP2018513368A (enExample)
KR (1) KR20170132318A (enExample)
CN (1) CN107636468A (enExample)
AU (1) AU2016240409A1 (enExample)
BR (1) BR112017021098A2 (enExample)
CA (1) CA2981533A1 (enExample)
WO (1) WO2016154682A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020261608A1 (ja) * 2019-06-28 2020-12-30 株式会社島津製作所 アミロイドβの脳内蓄積状態評価方法及び評価装置
WO2021039941A1 (ja) * 2019-08-30 2021-03-04 ニプロ株式会社 アルツハイマー型認知症又は軽度認知症を判別する方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10969453B2 (en) * 2016-01-22 2021-04-06 Synaptive Medical Inc. Systems and methods for magnetic field-dependent relaxometry using magnetic resonance imaging
WO2018064715A1 (en) * 2016-10-03 2018-04-12 Crc For Mental Health Ltd Method for predicting or diagnosing cognitive deterioration
CA3041648A1 (en) 2016-10-24 2018-05-03 Akili Interactive Labs, Inc. Cognitive platform configured as a biomarker or other type of marker
ES2942628T3 (es) * 2016-11-02 2023-06-05 Univ Kyushu Nat Univ Corp Método para determinar el riesgo de enfermedad de Alzheimer
EP3555841A4 (en) * 2016-12-13 2020-05-20 Akili Interactive Labs, Inc. BIOMARKER IDENTIFICATION PLATFORM USING NAVIGATION TASKS AND TREATMENTS USING NAVIGATION TASKS
WO2018148788A1 (en) * 2017-02-17 2018-08-23 Crc For Mental Health Ltd Method for predicting risk and rate of amyloid deposition and plaque formation
WO2018176082A1 (en) * 2017-03-28 2018-10-04 Crc For Mental Health Ltd Predicting progression of cognitive deterioration
JP6199520B1 (ja) * 2017-04-11 2017-09-20 株式会社アルム 保険管理装置、および保険管理システム
US11234657B2 (en) * 2017-05-01 2022-02-01 Rhode Island Hospital Non-invasive measurement to predict post-surgery anterior cruciate ligament success
KR102076091B1 (ko) * 2017-08-30 2020-02-11 사회복지법인 삼성생명공익재단 기억성 경도인지장애(aMCI) 환자에 대한 아밀로이드 페트 검사 양성률 예측 방법 및 장치
CN113508300A (zh) * 2018-10-04 2021-10-15 曼尼托巴大学 用于人类阿尔茨海默病的新型生物标记物
CN109464122B (zh) * 2018-11-05 2022-02-18 西南大学 基于多模态数据的个体核心特质预测系统及方法
MX2022002105A (es) * 2019-08-20 2022-08-04 Terran Biosciences Inc Imagenologia por resonancia magnetica (mri) sensible a neuromelanina para la evaluacion de la enfermedad de parkinson.
US11798652B2 (en) 2020-08-24 2023-10-24 Kpn Innovations, Llc. Method of and system for identifying and ameliorating body degradations
US11416776B2 (en) 2020-08-24 2022-08-16 Kpn Innovations, Llc. Method of and system for identifying and enumerating cross-body degradations
US11179110B1 (en) 2020-08-31 2021-11-23 Kpn Innovations Llc Method of system for reversing inflammation in a user
CN112526132A (zh) * 2020-11-23 2021-03-19 华中科技大学 预测2型糖尿病患者出现记忆力衰退的风险的方法
CN112353381B (zh) * 2020-11-24 2022-06-28 杭州冉曼智能科技有限公司 基于多模态大脑影像的阿尔茨海默症综合诊断系统
KR102406900B1 (ko) 2021-08-19 2022-06-08 의료법인 명지의료재단 노인 상태 개선 방법 및 시스템
KR102607398B1 (ko) * 2022-01-19 2023-11-29 이화여자대학교 산학협력단 뇌연령에 기초한 연령 관련 인지 저하 모니터링 방법 및 장치
CN114724709B (zh) * 2022-06-07 2022-10-14 深圳市铱硙医疗科技有限公司 基于vr眼动追踪的痴呆风险筛查系统、设备及介质
KR102771596B1 (ko) * 2022-07-14 2025-02-24 이화여자대학교 산학협력단 뇌영상으로부터 뇌성별 및 뇌연령을 예측하는 방법 및 장치
CN120089387B (zh) * 2025-05-07 2025-07-15 脑玺(苏州)智能科技有限公司 超早期认知下降状态的识别方法、装置及电子设备

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040101521A1 (en) * 2002-07-12 2004-05-27 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression
JP2005028151A (ja) * 2003-07-10 2005-02-03 General Electric Co <Ge> 磁気共鳴イメージングを用いて脳内鉄を検出するためのシステム及び方法
CN102743365A (zh) * 2011-04-19 2012-10-24 辽宁省计划生育科学研究院 一种化合物或其药学上可接受的盐在防治老年痴呆的应用
JP2014525340A (ja) * 2011-09-06 2014-09-29 ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド 組織内の異常物質の存在を検出するシステム及び方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60123431D1 (de) * 2000-07-25 2006-11-09 Sir Mortimer B Davis Jewish Ge Ho-1 suppressor als diagnostischer und prognostischer test für demenz-krankheiten
US20020165349A1 (en) * 2000-08-04 2002-11-07 Kirsch Wolff M. Iron regulating protein -2 (IRP-2) as a diagnostic for neurodegenerative disease
US20040102692A1 (en) * 2002-11-27 2004-05-27 General Electric Company Magnetic resonance imaging system and methods for the detection of brain iron deposits
US7728038B2 (en) * 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
US20110236917A1 (en) * 2009-11-17 2011-09-29 Power3 Medical Products, Inc. Diagnosis of Alzheimer's Disease
WO2012027794A2 (en) * 2010-09-01 2012-03-08 The Mental Health Research Institute Of Victoria Method of treatment and agents useful for same
CN103251932A (zh) * 2013-04-17 2013-08-21 钱忠明 铁调素在制备铁相关神经退行性疾病药物中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040101521A1 (en) * 2002-07-12 2004-05-27 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression
JP2005028151A (ja) * 2003-07-10 2005-02-03 General Electric Co <Ge> 磁気共鳴イメージングを用いて脳内鉄を検出するためのシステム及び方法
CN102743365A (zh) * 2011-04-19 2012-10-24 辽宁省计划生育科学研究院 一种化合物或其药学上可接受的盐在防治老年痴呆的应用
JP2014525340A (ja) * 2011-09-06 2014-09-29 ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド 組織内の異常物質の存在を検出するシステム及び方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020261608A1 (ja) * 2019-06-28 2020-12-30 株式会社島津製作所 アミロイドβの脳内蓄積状態評価方法及び評価装置
WO2021039941A1 (ja) * 2019-08-30 2021-03-04 ニプロ株式会社 アルツハイマー型認知症又は軽度認知症を判別する方法

Also Published As

Publication number Publication date
CA2981533A1 (en) 2016-10-06
EP3278113A4 (en) 2018-11-21
KR20170132318A (ko) 2017-12-01
CN107636468A (zh) 2018-01-26
US20180284141A1 (en) 2018-10-04
BR112017021098A2 (pt) 2018-07-03
WO2016154682A1 (en) 2016-10-06
AU2016240409A1 (en) 2017-11-09
EP3278113A1 (en) 2018-02-07

Similar Documents

Publication Publication Date Title
JP2018513368A (ja) 認知力低下のリスクを予測するための方法
Chen et al. Plasma Aβ42 and total tau predict cognitive decline in amnestic mild cognitive impairment
US9726678B2 (en) Methods and compositions for the diagnosis and prognosis of Alzheimer&#39;s disease
US20130116135A1 (en) Methods, Kits and Reagents for Diagnosing, Alding Diagnosis and/or Monitoring Progression of a Neurological Disorder
AU2016266053A1 (en) Method for detection of a neurological disease
Babapour Mofrad et al. Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status
Wang et al. Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer’s disease
JP2025118826A (ja) アルツハイマー病を判定するためのタンパク質マーカー
JP6199880B2 (ja) 脳卒中の診断を補助するためのバイオマーカーに基づく方法およびバイオチップ
EP3982819A1 (en) Methods for evaluation and treatment of alzheimer&#39;s disease and applications thereof
Youn et al. Urine neural thread protein measurements in Alzheimer disease
WO2010011555A1 (en) Csf biomarkers for the prediction of cognitive decline in alzheimer&#39;s disease patients
Mnich et al. Endoplasmic reticulum stress-regulated chaperones as a serum biomarker panel for Parkinson’s disease
WO2015174544A1 (ja) 精神疾患判定マーカー
WO2008144613A1 (en) Biomarkers for the diagnosis and assessment of bipolar disorder
JP7713445B2 (ja) 薬物誘発細胞毒性及び鬱病のバイオマーカー
Che et al. Plasma placental growth factor as a biomarker for subcortical ischemic vascular dementia and its cognitive correlation mediated by white matter hyperintensities
WO2018148788A1 (en) Method for predicting risk and rate of amyloid deposition and plaque formation
JP2025016807A (ja) 脳内アミロイドβの蓄積を評価するためのバイオマーカー
WO2016160484A1 (en) Novel biomarkers for psychiatric disorders
van der Ende Fluid Biomarkers in Genetic Frontotemporal Dementia
Abdi Discovery and Development of Biomarkers for Parkinson’s Disease and Related Disorders
van der Ende Fluid biomarkers in frontotemporal dementia: past, present and future
CN121152975A (zh) 用于确定神经退行性疾病治疗的功效的方法
HK40083580A (en) Protein markers for assessing alzheimer&#39;s disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190329

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200901